Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
60 Degrees Pharmaceuticals, Inc. (SXTP)
NASDAQ:SXTP
RESEARCH TOOLSreports
Holding SXTP?
Track your performance easily
SXTP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.70 - $18.36
Previous Close$0.99
Volume29.29K
Average Volume (3M)176.73K
Market Cap
$1.84M
Enterprise Value$1.77M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)1.6
Beta2.46
Next Earnings
May 15, 2024EPS Estimate
-$2.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.63
Shares Outstanding1,768,337
10 Day Avg. Volume103,597
30 Day Avg. Volume176,734
Standard Deviation0.33
R-Squared0.30
Alpha-0.22
Financial Highlights & Ratios
Price to Book (P/B)-0.26
Price to Sales (P/S)5.98
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.63
Enterprise Value/Gross Profit-8.00
Enterprise Value/Ebitda0.52
Forecast
1Y Price Target
$5.50Price Target Upside444.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
60 Degrees Pharmaceuticals, Inc. News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsClinical trial agreements have been signed with Yale, Tufts, and Rhode Island Hospital to study Tafenoquine for Babesiosis, aiming for a potential NDA filing by Q2 of FY26.
Drug DevelopmentArakoda was recently granted FDA Orphan Drug Designation for the treatment of babesiosis.
Product PerformanceArakoda boxes sold grew 288% YoY.
Bears Say
Financial PerformanceQ2 FY24 results showed revenues of $125,000, which were below the estimate of $170,000, and a pro-forma EPS of $(4.24) was impacted by a non-cash R&D charge.
Funding And Cash FlowThe company is expected to need to raise additional funds by Q1 of FY25 due to a cash burn rate of $1-1.3 million per quarter.
Research And Development Spending2Q24 R&D expenses were $3.1M, compared to $0.2M in 2Q23.
---
Options Prices
Currently, No data available
---
Ownership Overview
59.16% Insiders
0.17% Mutual Funds
― Other Institutional Investors
40.64% Public Companies and
Individual Investors
SXTP FAQ
What was 60 Degrees Pharmaceuticals, Inc.’s price range in the past 12 months?
60 Degrees Pharmaceuticals, Inc. lowest stock price was $0.70 and its highest was $18.36 in the past 12 months.
What is 60 Degrees Pharmaceuticals, Inc.’s market cap?
Currently, no data Available
When is 60 Degrees Pharmaceuticals, Inc.’s upcoming earnings report date?
60 Degrees Pharmaceuticals, Inc.’s upcoming earnings report date is May 15, 2024 which is 190 days ago.
How were 60 Degrees Pharmaceuticals, Inc.’s earnings last quarter?
Currently, no data Available
Is 60 Degrees Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts 60 Degrees Pharmaceuticals, Inc.’s price is currently Undervalued.
Does 60 Degrees Pharmaceuticals, Inc. pay dividends?
60 Degrees Pharmaceuticals, Inc. does not currently pay dividends.
What is 60 Degrees Pharmaceuticals, Inc.’s EPS estimate?
60 Degrees Pharmaceuticals, Inc.’s EPS estimate is -$2.28.
How many shares outstanding does 60 Degrees Pharmaceuticals, Inc. have?
60 Degrees Pharmaceuticals, Inc. has 1,861,914 shares outstanding.
What happened to 60 Degrees Pharmaceuticals, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of 60 Degrees Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in SXTP
---
60 Degrees Pharmaceuticals, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.50 (444.55% Upside)
$5.50 (444.55% Upside)
Insider Transactions
Bought Shares
Worth $8.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▲ 4.7%
Last 30 Days ▲ 4.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-85.52%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-41.20%
Trailing 12-Months
Company Description
60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Its lead product, ARAKODA (tafenoquine), is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years and older. The Company's pipeline under development covers development programs for COVID-19, fungal, tick-borne, and other viral diseases; new products that contain the Arakoda regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. The ARAKODA regimen of tafenoquine is in Phase II study data in patients with mild-moderate COVID-19 disease. It is also planning a clinical study to assess the utility of ARAKODA as a treatment for human babesiosis. The Company is also developing Celgosivir for the treatment of COVID-19, respiratory syncytial virus (RSV), and dengue.
---
SXTP Stock 12 Month Forecast
Average Price Target
$5.50
▲(444.55% Upside)
Technical Analysis
Best Analysts Covering SXTP
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-65.77%
reiterated a buy rating 3 months ago
Copying Lucas Ward's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -65.77% per trade.
---